Blocking SHCBP1–PLK1 complex using targeted TFBG agent renders gastric cancer sensitive to HER2-directed therapy, providing additional combination therapy in HER2-positive patients with advanced gastric cancer. This evidence concerns the gene SHCBP1 and gastric cancer.